Alexej Ballhausen, MD, Charité, Berlin, Germany, comments on practice-changing gastrointestinal cancer trials that have recently been publicized over the past year, including the NICHE-2 trial (NL58483.031.16, EudraCT 016-002940-17), which assessed immune checkpoint inhibitors in the neoadjuvant setting in patients with mismatch repair deficient (dMMR) colon cancer. Dr Ballhausen additionally mentions the INFINITY trial (NCT04817826) of immunotherapy in patients with MSI-high gastric/gastroesophageal junction cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.